Literature DB >> 10891656

Bactericidal antibody response to Neisseria meningitidis serogroup B in patients with bacterial meningitis: effect of immunization with an outer membrane protein vaccine.

L G Milagres1, M C Gorla, M C Rebelo, D E Barroso.   

Abstract

We evaluated the bactericidal antibody response to Neisseria meningitidis serogroup B in convalescent patients (n=65) from bacterial meningitis. Patients infected with B meningococci were stratified according to their vaccination status (Cuban BC vaccine) into group 1 (immunized) (n=12) and group 2 (non-immunized) (n=15). The results suggested that antibody titers > or =2 (log(2)) indicate a specific immune response to N. meningitidis. In group 1, 64% of patients had a significant antibody titer (> or =2) in their acute sera against a B:4:P1.15 strain, compared to only 21% of group 2 patients. All patients from group 1 without bactericidal antibodies in their acute sera had a significant increase (at least 2-fold increase in log(2) titers) in antibody titers in their convalescent sera, in contrast, to only 27% of patients from group 2 (P=0.06). Using mutant strains lacking OMP1 or OMP5, it was shown that OMP1 was an important antigen recognized by immunized patients but not by non-immunized patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10891656     DOI: 10.1111/j.1574-695X.2000.tb01493.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  6 in total

1.  Sterilizing immunity elicited by Neisseria meningitidis carriage shows broader protection than predicted by serum antibody cross-reactivity in CEACAM1-humanized mice.

Authors:  Kay O Johswich; Shannon E McCaw; Lea Strobel; Matthias Frosch; Scott D Gray-Owen
Journal:  Infect Immun       Date:  2014-11-03       Impact factor: 3.441

2.  Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac.

Authors:  Jamie Findlow; Stephen Taylor; Audun Aase; Rachel Horton; Robert Heyderman; Jo Southern; Nick Andrews; Rita Barchha; Ewan Harrison; Ann Lowe; Emma Boxer; Charlotte Heaton; Paul Balmer; Ed Kaczmarski; Philipp Oster; Andrew Gorringe; Ray Borrow; Elizabeth Miller
Journal:  Infect Immun       Date:  2006-08       Impact factor: 3.441

3.  Comparison of phenotypically indistinguishable but geographically distinct Neisseria meningitidis Group B isolates in a serum bactericidal antibody assay.

Authors:  Jamie Findlow; Ann Holland; Nick Andrews; Vincent Weynants; Franklin Sotolongo; Paul Balmer; Jan Poolman; Ray Borrow
Journal:  Clin Vaccine Immunol       Date:  2007-09-19

4.  Antibody specificities and effect of meningococcal carriage in icelandic teenagers receiving the Norwegian serogroup B outer membrane vesicle vaccine.

Authors:  Elisabeth Wedege; Betsy Kuipers; Karin Bolstad; Harry van Dijken; L Oddvar Frøholm; Clementien Vermont; Dominique A Caugant; Germie van den Dobbelsteen
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

5.  Immunogenicity profiling of protein antigens from capsular group B Neisseria meningitidis.

Authors:  Amaka M Awanye; Chun-Mien Chang; Jun X Wheeler; Hannah Chan; Leanne Marsay; Christina Dold; Christine S Rollier; Louise E Bird; Joanne E Nettleship; Raymond J Owens; Andrew J Pollard; Jeremy P Derrick
Journal:  Sci Rep       Date:  2019-05-02       Impact factor: 4.379

Review 6.  Prospects for eradication of meningococcal disease.

Authors:  Simon Nadel
Journal:  Arch Dis Child       Date:  2012-09-15       Impact factor: 3.791

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.